Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections

Seminars in Respiratory and Critical Care Medicine

Volumn 36, Issue 5, 2015, Pages 767-785

  Clark, Nina M ^a   Grim, Shellee A ^a,b   Lynch, Joseph P ^c  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aspergillus; azoles; fungal infections; mold infections; mucormycosis; posaconazole

Indexed keywords

POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ABSIDIA; AJELLOMYCES CAPSULATUS; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; BLASTOMYCOSIS; CANDIDA; CANDIDIASIS; CHOLESTASIS; CHROMOMYCOSIS; CLINICAL TRIAL (TOPIC); COCCIDIOIDES IMMITIS; COCCIDIOIDOMYCOSIS; CONTROLLED CLINICAL TRIAL (TOPIC); CRYPTOCOCCUS NEOFORMANS; CUNNINGHAMELLA; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SENSITIZATION; DRUG USE; FEBRILE NEUTROPENIA; FILAMENTOUS FUNGUS; FILOBASIDIELLA; FUNGAL COLONIZATION; FUSARIOSIS; FUSARIUM; FUSARIUM SOLANI; HEADACHE; HIGH RISK PATIENT; HISTOPLASMOSIS; HUMAN; HYALOHYPHOMYCOSIS; HYPERTRANSAMINASEMIA; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; LIVER FAILURE; LIVER TOXICITY; LUNG ASPERGILLOSIS; MUCOR; MUCORMYCOSIS; MYCOSIS; NAUSEA; NONHUMAN; OROPHARYNX CANDIDIASIS; PRIORITY JOURNAL; PROPHYLAXIS; PSEUDALLESCHERIASIS; QT INTERVAL; RASH; RHIZOMUCOR; RHIZOPUS; SCEDOSPORIUM; SEVERE HEPATIC IMPAIRMENT; SOMNOLENCE; TORSADE DES POINTES; TREATMENT DURATION; TRICHOPHYTON RUBRUM; UNITED STATES; VOLUME OF DISTRIBUTION; VOMITING; XEROSTOMIA; ANTIFUNGAL RESISTANCE; CLASSIFICATION; DRUG INTERACTION; FOOD AND DRUG ADMINISTRATION; GRAFT RECIPIENT; MYCOSES; PROCEDURES; SALVAGE THERAPY;

ANTIFUNGAL AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, FUNGAL; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; SALVAGE THERAPY; TRANSPLANT RECIPIENTS; TRIAZOLES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84942251059     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0035-1562902     Document Type: Article

References (265)

1. Noxafil [package insert]. Whitehouse Station, NJ Merck & Co., Inc.: 2014
2. Cornely O. A., Maertens J., Winston D. J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med: 2007; 356 4 348 359
3. Ullmann A. J., Lipton J. H., Vesole D. H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med: 2007; 356 4 335 347
4. Vazquez J. A., Skiest D. J., Nieto L., et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis: 2006; 42 8 1179 1186
5. Skiest D. J., Vazquez J. A., Anstead G. M., et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis: 2007; 44 4 607 614
6. Noxafil: EPAR-Summary for the public. 2014. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/000610/WC500037785.pdf. Accessed November 26, 2014
7. Walsh T. J., Raad I., Patterson T. F., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis: 2007; 44 1 2 12
8. Heinz W. J., Egerer G., Lellek H., Boehme A., Greiner J. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. Mycoses: 2013; 56 3 304 310
9. van Burik J. A., Hare R. S., Solomon H. F., Corrado M. L., Kontoyiannis D. P. Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases. Clin Infect Dis: 2006; 42 7 e61 e65
10. Greenberg R. N., Mullane K., van Burik J. A., et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother: 2006; 50 1 126 133
11. Proia L. A., Harnisch D. O. Successful use of posaconazole for treatment of blastomycosis. Antimicrob Agents Chemother: 2012; 56 7 4029
12. Kim M. M., Vikram H. R., Kusne S., Seville M. T., Blair J. E. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis: 2011; 53 11 1060 1066
13. Schein R., Homans J., Larsen R. A., Neely M. Posaconazole for chronic refractory coccidioidal meningitis. Clin Infect Dis: 2011; 53 12 1252 1254
14. Restrepo A., Tobón A., Clark B., et al. Salvage treatment of histoplasmosis with posaconazole. J Infect: 2007; 54 4 319 327
15. Döring M., Blume O., Haufe S., et al. Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis: 2014; 33 4 629 638
16. Döring M., Müller C., Johann P. D., et al. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect Dis: 2012; 12 263
17. Cesaro S., Milano G. M., Aversa F. Retrospective survey on the off-label use of posaconazole in pediatric hematology patients. Eur J Clin Microbiol Infect Dis: 2011; 30 4 595 596
18. Lehrnbecher T., Attarbaschi A., Duerken M., et al. Posaconazole salvage treatment in paediatric patients: A multicentre survey. Eur J Clin Microbiol Infect Dis: 2010; 29 8 1043 1045
19. Zonios D. I., Bennett J. E. Update on azole antifungals. Semin Respir Crit Care Med: 2008; 29 2 198 210
20. Pasqualotto A. C., Thiele K. O., Goldani L. Z. Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole. Curr Opin Investig Drugs: 2010; 11 2 165 174
21. Torres H. A., Hachem R. Y., Chemaly R. F., Kontoyiannis D. P., Raad I. I. Posaconazole: A broad-spectrum triazole antifungal. Lancet Infect Dis: 2005; 5 12 775 785
22. Katragkou A., Tsikopoulou F., Roilides E., Zaoutis T. E. Posaconazole: when and how? The clinician's view. Mycoses: 2012; 55 2 110 122
23. Keating G. M. Posaconazole. Drugs: 2005; 65 11 1553 1567, discussion 1568-1569
24. Kauffman C. A., Malani A. N., Easley C., Kirkpatrick P. Posaconazole. Nat Rev Drug Discov: 2007; 6 3 183 184
25. Ma L. J., Ibrahim A. S., Skory C., et al. Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet: 2009; 5 7 e1000549
26. Schwartze V. U., Winter S., Shelest E., et al. Gene expansion shapes genome architecture in the human pathogen Lichtheimia corymbifera: An evolutionary genomics analysis in the ancient terrestrial Mucorales (Mucoromycotina). PLoS Genet: 2014; 10 8 e1004496
27. Lewis R. E., Ben-Ami R., Best L., Albert N., Walsh T. J., Kontoyiannis D. P. Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis. J Infect Dis: 2013; 207 5 834 841
28. Castanheira M., Messer S. A., Jones R. N., Farrell D. J., Pfaller M. A. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. Int J Antimicrob Agents: 2014; 44 4 320 326
29. Pfaller M. A., Diekema D. J. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol: 2012; 50 9 2846 2856
30. Pfaller M. A., Messer S. A., Woosley L. N., Jones R. N., Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: Application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol: 2013; 51 8 2571 2581
31. Pfaller M. A., Moet G. J., Messer S. A., Jones R. N., Castanheira M. Candida bloodstream infections: Comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother: 2011; 55 2 561 566
32. Sabatelli F., Patel R., Mann P. A., et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother: 2006; 50 6 2009 2015
33. Ramani R., Chaturvedi V. Antifungal susceptibility profiles of Coccidioides immitis and Coccidioides posadasii from endemic and non-endemic areas. Mycopathologia: 2007; 163 6 315 319
34. Wheat L. J., Connolly P., Smedema M., et al. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother: 2006; 57 6 1235 1239
35. Sugar A. M., Liu X. P. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother: 1996; 40 5 1314 1316
36. Diekema D. J., Messer S. A., Hollis R. J., Jones R. N., Pfaller M. A. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol: 2003; 41 8 3623 3626
37. Pfaller M. A., Messer S. A., Hollis R. J., Jones R. N.; SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother: 2002; 46 4 1032 1037
38. Drogari-Apiranthitou M., Mantopoulou F. D., Skiada A., et al. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs. J Antimicrob Chemother: 2012; 67 8 1937 1940
39. Almyroudis N. G., Sutton D. A., Fothergill A. W., Rinaldi M. G., Kusne S. In vitro susceptibilities of 217 clinical isolates of Zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother: 2007; 51 7 2587 2590
40. de Macedo-Silva S. T., Urbina J. A., de Souza W., Rodrigues J. C. In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania amazonensis. PLoS ONE: 2013; 8 12 e83247
41. Paniz Mondolfi A. E., Stavropoulos C., Gelanew T., et al. Successful treatment of Old World cutaneous leishmaniasis caused by Leishmania infantum with posaconazole. Antimicrob Agents Chemother: 2011; 55 4 1774 1776
42. Molina I., Gómez i Prat J., Salvador F., et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med: 2014; 370 20 1899 1908
43. Roberts C. W., McLeod R., Rice D. W., Ginger M., Chance M. L., Goad L. J. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol Biochem Parasitol: 2003; 126 2 129 142
44. Arendrup M. C., Cuenca-Estrella M., Donnelly J. P., Hope W., Lass-FlÖrl C., Rodriguez-Tudela J. L. European Committee on Antimicrobial Susceptibility Testing - Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). Clin Microbiol Infect 17 11 E16 7
45. Pfaller M. A., Messer S. A., Boyken L., Tendolkar S., Hollis R. J., Diekema D. J. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol: 2008; 46 2 551 559
46. Pfaller M. A., Diekema D. J. Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance. J Invasive Fungal Infect: 2007; 1 74
47. Barchiesi F., Spreghini E., Schimizzi A. M., et al. Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection. Antimicrob Agents Chemother: 2004; 48 9 3312 3316
48. Ballester F., Pastor F. J., Guarro J. In vitro activities of combinations of amphotericin B, posaconazole and four other agents against Rhizopus. J Antimicrob Chemother: 2008; 61 3 755 757
49. Guembe M., Guinea J., Peláez T., Torres-Narbona M., Bouza E. Synergistic effect of posaconazole and caspofungin against clinical Zygomycetes. Antimicrob Agents Chemother: 2007; 51 9 3457 3458
50. Perkhofer S., Locher M., Cuenca-Estrella M., et al. Posaconazole enhances the activity of amphotericin B against hyphae of Zygomycetes in vitro. Antimicrob Agents Chemother: 2008; 52 7 2636 2638
51. Arikan S., Sancak B., Alp S., Hascelik G., McNicholas P. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol: 2008; 46 6 567 573
52. Najvar L. K., Cacciapuoti A., Hernandez S., et al. Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: Comparative studies in two laboratories. Antimicrob Agents Chemother: 2004; 48 3 758 764
53. Lepak A. J., Marchillo K., VanHecker J., Andes D. R. Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates. Antimicrob Agents Chemother: 2013; 57 11 5438 5447
54. Walsh T. J., Anaissie E. J., Denning D. W., et al. Infectious Diseases Society of America. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis: 2008; 46 3 327 360
55. Maertens J., Marchetti O., Herbrecht R., et al. Third European Conference on Infections in Leukemia. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant: 2011; 46 5 709 718
56. Skiada A., Lanternier F., Groll A. H., et al. European Conference on Infections in Leukemia. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica: 2013; 98 4 492 504
57. Ananda-Rajah M. R., Grigg A., Downey M. T., et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica: 2012; 97 3 459 463
58. Rogers T. R., Slavin M. A., Donnelly J. P. Antifungal prophylaxis during treatment for haematological malignancies: Are we there yet? Br J Haematol: 2011; 153 6 681 697
59. Vehreschild J. J., Rüping M. J., Wisplinghoff H., et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): A 6 year experience of the Cologne AML cohort. J Antimicrob Chemother: 2010; 65 7 1466 1471
60. Girmenia C., Frustaci A. M., Gentile G., et al. Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: A single-center, real-life experience. Haematologica: 2012; 97 4 560 567
61. Kung H. C., Johnson M. D., Drew R. H., Saha-Chaudhuri P., Perfect J. R. Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: A retrospective cohort study. Cancer Med: 2014; 3 3 667 673
62. Gomes M. Z., Mulanovich V. E., Jiang Y., Lewis R. E., Kontoyiannis D. P. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011. Antimicrob Agents Chemother: 2014; 58 2 865 873
63. Pechlivanoglou P., Le H. H., Daenen S., Snowden J. A., Postma M. J. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: A systematic review. J Antimicrob Chemother: 2014; 69 1 1 11
64. Gomes M. Z., Jiang Y., Mulanovich V. E., Lewis R. E., Kontoyiannis D. P. Effectiveness of primary anti- Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia. Antimicrob Agents Chemother: 2014; 58 5 2775 2780
65. Denning D. W., Bowyer P. Voriconazole resistance in Aspergillus fumigatus: should we be concerned? Clin Infect Dis: 2013; 57 4 521 523
66. Freifeld A. G., Bow E. J., Sepkowitz K. A., et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis: 2011; 52 4 e56 e93
67. Nagappan V., Deresinski S. Reviews of anti-infective agents: posaconazole: A broad-spectrum triazole antifungal agent. Clin Infect Dis: 2007; 45 12 1610 1617
68. Baddley J. W., Andes D. R., Marr K. A., et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis: 2010; 50 12 1559 1567
69. Singh N., Paterson D. L. Aspergillus infections in transplant recipients. Clin Microbiol Rev: 2005; 18 1 44 69
70. Thompson G. R. III, Patterson T. F. Pulmonary aspergillosis: recent advances. Semin Respir Crit Care Med: 2011; 32 6 673 681
71. Herbrecht R., Denning D. W., Patterson T. F., et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med: 2002; 347 6 408 415
72. Kepenekli E., Soysal A., Kuzdan C., Ermerak N. O., Yüksel M., Baklr M. Refractory invasive aspergillosis controlled with posaconazole and pulmonary surgery in a patient with chronic granulomatous disease: Case report. Ital J Pediatr: 2014; 40 2
73. Raad I. I., Hanna H. A., Boktour M., et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia: 2008; 22 3 496 503
74. Alexander B. D., Perfect J. R., Daly J. S., et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation: 2008; 86 6 791 796
75. Felton T. W., Baxter C., Moore C. B., Roberts S. A., Hope W. W., Denning D. W. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis: 2010; 51 12 1383 1391
76. Chishimba L., Niven R. M., Cooley J., Denning D. W. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. J Asthma: 2012; 49 4 423 433
77. Cornely O. A., Bassetti M., Calandra T., et al. ESCMID Fungal Infection Study Group. ESCMID∗ guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect: 2012; 18 07 19 37
78. Pappas P. G., Kauffman C. A., Andes D., et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis: 2009; 48 5 503 535
79. Kett D. H., Azoulay E., Echeverria P. M., Vincent J. L.; Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators. Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med: 2011; 39 4 665 670
80. Ruhnke M., Rickerts V., Cornely O. A., et al. German Speaking Mycological Society; Paul-Ehrlich-Society for Chemotherapy. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses: 2011; 54 4 279 310
81. Colombo A. L., Guimarães T., Camargo L. F., et al. Brazilian guidelines for the management of candidiasis - a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical. Braz J Infect Dis: 2013; 17 3 283 312
82. Firinu D., Massidda O., Lorrai M. M., et al. Successful treatment of chronic mucocutaneous candidiasis caused by azole-resistant Candida albicans with posaconazole. Clin Dev Immunol: 2011; 2011 283239
83. Perfect J. R., Dismukes W. E., Dromer F., et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis: 2010; 50 3 291 322
84. Espinel-Ingroff A., Aller A. I., Canton E., et al. Cryptococcus neoformans - Cryptococcus gattii species complex: An international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother: 2012; 56 11 5898 5906
85. Lockhart S. R., Iqbal N., Bolden C. B., et al. Cryptococcus gattii PNW Public Health Working Group. Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: Correlation of molecular type and in vitro susceptibility. Diagn Microbiol Infect Dis: 2012; 73 2 144 148
86. Pfaller M. A., Castanheira M., Diekema D. J., Messer S. A., Jones R. N. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. Diagn Microbiol Infect Dis: 2011; 71 3 252 259
87. Cleveland K. O., Gelfand M. S., Rao V. Posaconazole as successful treatment for fungemia due to Cryptococcus albidus in a liver transplant recipient. QJM: 2013; 106 4 361 362
88. Esposito V., Viglietti R., Gargiulo M., et al. Successful treatment of Cryptococcal meningitis with a combination of liposomal amphotericin B, flucytosine and posaconazole: two case reports. In Vivo: 2009; 23 3 465 468
89. Day S. R., Weiss D. B., Hazen K. C., Moore C. C. Successful treatment of osseous blastomycosis without pulmonary or disseminated disease and review of the literature. Diagn Microbiol Infect Dis: 2014; 79 2 242 244
90. McKinsey D. S., McKinsey J. P. Pulmonary histoplasmosis. Semin Respir Crit Care Med: 2011; 32 6 735 744
91. Gonçalves D., Ferraz C., Vaz L. Posaconazole as rescue therapy in African histoplasmosis. Braz J Infect Dis: 2013; 17 1 102 105
92. Catanzaro A., Cloud G. A., Stevens D. A., et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis: 2007; 45 5 562 568
93. Anstead G. M., Corcoran G., Lewis J., Berg D., Graybill J. R. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis: 2005; 40 12 1770 1776
94. Stevens D. A., Rendon A., Gaona-Flores V., et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest: 2007; 132 3 952 958
95. Dismukes W. E., Bradsher R. W. Jr, Cloud G. C., et al. NIAID Mycoses Study Group. Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med: 1992; 93 5 489 497
96. Chapman S. W., Dismukes W. E., Proia L. A., et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis: 2008; 46 12 1801 1812
97. Bradsher R. W. Blastomycosis. Clin Infect Dis: 1992; 14 01 S82 S90
98. Borgia S. M., Fuller J. D., Sarabia A., El-Helou P. Cerebral blastomycosis: A case series incorporating voriconazole in the treatment regimen. Med Mycol: 2006; 44 7 659 664
99. Bakleh M., Aksamit A. J., Tleyjeh I. M., Marshall W. F. Successful treatment of cerebral blastomycosis with voriconazole. Clin Infect Dis: 2005; 40 9 e69 e71
100. Panicker J., Walsh T., Kamani N. Recurrent central nervous system blastomycosis in an immunocompetent child treated successfully with sequential liposomal amphotericin B and voriconazole. Pediatr Infect Dis J: 2006; 25 4 377 379
101. Bariola J. R., Perry P., Pappas P. G., et al. Blastomycosis of the central nervous system: A multicenter review of diagnosis and treatment in the modern era. Clin Infect Dis: 2010; 50 6 797 804
102. Grim S. A., Proia L., Miller R., et al. A multicenter study of histoplasmosis and blastomycosis after solid organ transplantation. Transpl Infect Dis: 2012; 14 1 17 23
103. Galgiani J. N., Ampel N. M., Blair J. E., et al. Infectious Diseases Society of America. Coccidioidomycosis. Clin Infect Dis: 2005; 41 9 1217 1223
104. Proia L. A., Tenorio A. R. Successful use of voriconazole for treatment of Coccidioides meningitis. Antimicrob Agents Chemother: 2004; 48 6 2341
105. Freifeld A., Proia L., Andes D., et al. Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother: 2009; 53 4 1648 1651
106. Levy E. R., McCarty J. M., Shane A. L., Weintrub P. S. Treatment of pediatric refractory coccidioidomycosis with combination voriconazole and caspofungin: A retrospective case series. Clin Infect Dis: 2013; 56 11 1573 1578
107. Prabhu R. M., Bonnell M., Currier B. L., Orenstein R. Successful treatment of disseminated nonmeningeal coccidioidomycosis with voriconazole. Clin Infect Dis: 2004; 39 7 e74 e77
108. Limper A. H., Knox K. S., Sarosi G. A., et al. American Thoracic Society Fungal Working Group. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med: 2011; 183 1 96 128
109. Wheat L. J., Freifeld A. G., Kleiman M. B., et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis: 2007; 45 7 807 825
110. Connolly P., Wheat J., Schnizlein-Bick C., et al. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother: 1999; 43 2 322 328
111. Connolly P., Wheat L. J., Schnizlein-Bick C., et al. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob Agents Chemother: 2000; 44 10 2604 2608
112. Freifeld A. G., Wheat L. J., Kaul D. R. Histoplasmosis in solid organ transplant recipients: early diagnosis and treatment. Curr Opin Organ Transplant: 2009; 14 6 601 605
113. Dhawan J., Verma P., Sharma A., Ramam M., Kabra S. K., Gupta S. Disseminated cutaneous histoplasmosis in an immunocompetent child, relapsed with itraconazole, successfully treated with voriconazole. Pediatr Dermatol: 2010; 27 5 549 551
114. Srinivasan J., Ooi W. W. Successful treatment of histoplasmosis brain abscess with voriconazole. Arch Neurol: 2008; 65 5 666 667
115. Clark B., Foster R., Tunbridge A., Green S. A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole. J Infect: 2005; 51 3 e177 e180
116. Kwon-Chung K. J. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis: 2012; 54 01 S8 S15
117. Rüping M. J., Heinz W. J., Kindo A. J., et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother: 2010; 65 2 296 302
118. Skiada A., Pagano L., Groll A., et al. European Confederation of Medical Mycology Working Group on Zygomycosis. Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect: 2011; 17 12 1859 1867
119. Cornely O. A., Arikan-Akdagli S., Dannaoui E., et al. European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group; European Confederation of Medical Mycology. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect: 2014; 20 03 5 26
120. Roden M. M., Zaoutis T. E., Buchanan W. L., et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis: 2005; 41 5 634 653
121. Doligalski C. T., Benedict K., Cleveland A. A., et al. Epidemiology of invasive mold infections in lung transplant recipients. Am J Transplant: 2014; 14 6 1328 1333
122. Hamilos G., Samonis G., Kontoyiannis D. P. Pulmonary mucormycosis. Semin Respir Crit Care Med: 2011; 32 6 693 702
123. Mitchell T. A., Hardin M. O., Murray C. K., et al. Mucormycosis attributed mortality: A seven-year review of surgical and medical management. Burns: 2014; 40 8 1689 1695
124. Pyrgos V., Shoham S., Walsh T. J. Pulmonary zygomycosis. Semin Respir Crit Care Med: 2008; 29 2 111 120
125. Lanternier F., Dannaoui E., Morizot G., et al. French Mycosis Study Group. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis: 2012; 54 01 S35 S43
126. Vehreschild J. J., Birtel A., Vehreschild M. J., et al. Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol: 2013; 39 3 310 324
127. Bitar D., Van Cauteren D., Lanternier F., et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis: 2009; 15 9 1395 1401
128. Bitar D., Lortholary O., Le Strat Y., et al. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis: 2014; 20 7 1149 1155
129. Saegeman V., Maertens J., Meersseman W., Spriet I., Verbeken E., Lagrou K. Increasing incidence of mucormycosis in University Hospital, Belgium. Emerg Infect Dis: 2010; 16 9 1456 1458
130. Chamilos G., Luna M., Lewis R. E., et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: An autopsy study over a 15-year period (1989-2003). Haematologica: 2006; 91 7 986 989
131. Abidi M. Z., Sohail M. R., Cummins N., et al. Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: A comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies. Mycoses: 2014; 57 11 687 698
132. Trifilio S. M., Bennett C. L., Yarnold P. R., et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant: 2007; 39 7 425 429
133. Pongas G. N., Lewis R. E., Samonis G., Kontoyiannis D. P. Voriconazole-associated zygomycosis: A significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin Microbiol Infect: 2009; 15 05 93 97
134. Auberger J., Lass-Flörl C., Aigner M., Clausen J., Gastl G., Nachbaur D. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. J Antimicrob Chemother: 2012; 67 9 2268 2273
135. Lerolle N., Raffoux E., Socie G., et al. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: A 4-year study. Clin Microbiol Infect: 2014; 20 11 O952 O959
136. Marty F. M., Cosimi L. A., Baden L. R. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med: 2004; 350 9 950 952
137. Siwek G. T., Dodgson K. J., de Magalhaes-Silverman M., et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis: 2004; 39 4 584 587
138. Imhof A., Balajee S. A., Fredricks D. N., Englund J. A., Marr K. A. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis: 2004; 39 5 743 746
139. Tacke D., Koehler P., Markiefka B., Cornely O. A. Our 2014 approach to mucormycosis. Mycoses: 2014; 57 9 519 524
140. Cornely O. A., Vehreschild J. J., Rüping M. J. Current experience in treating invasive zygomycosis with posaconazole. Clin Microbiol Infect: 2009; 15 05 77 81
141. Lanternier F., Sun H. Y., Ribaud P., Singh N., Kontoyiannis D. P., Lortholary O. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis: 2012; 54 11 1629 1636
142. Sun H. Y., Forrest G., Gupta K. L., et al. Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients. Transplantation: 2010; 90 1 85 92
143. Tedder M., Spratt J. A., Anstadt M. P., Hegde S. S., Tedder S. D., Lowe J. E. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg: 1994; 57 4 1044 1050
144. Abboud C. S., Bergamasco M. D., Baía C. E., et al. Case report of hepatic mucormycosis after liver transplantation: successful treatment with liposomal amphotericin B followed by posaconazole sequential therapy. Transplant Proc: 2012; 44 8 2501 2502
145. Tobón A. M., Arango M., Fernández D., Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis: 2003; 36 11 1488 1491
146. Ashkenazi-Hoffnung L., Bilavsky E., Avitzur Y., Amir J. Successful treatment of cutaneous zygomycosis with intravenous amphotericin B followed by oral posaconazole in a multivisceral transplant recipient. Transplantation: 2010; 90 10 1133 1135
147. Kulendra K., Habibi M., Butler C., Clarke P., Howard D. Use of posaconazole in the treatment of infective rhinocerebral mucormycosis. J Laryngol Otol: 2010; 124 12 1314 1317
148. Pagano L., Cornely O. A., Busca A., et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: A report from the SEIFEM and FUNGISCOPE registries. Haematologica: 2013; 98 10 e127 e130
149. Varkey J. B., Perfect J. R. Rare and emerging fungal pulmonary infections. Semin Respir Crit Care Med: 2008; 29 2 121 131
150. Chen S. C., Blyth C. C., Sorrell T. C., Slavin M. A. Pneumonia and lung infections due to emerging and unusual fungal pathogens. Semin Respir Crit Care Med: 2011; 32 6 703 716
151. Tortorano A. M., Richardson M., Roilides E., et al. European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group; European Confederation of Medical Mycology. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect: 2014; 20 03 27 46
152. Husain S., Muñoz P., Forrest G., et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: Clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis: 2005; 40 1 89 99
153. Lackner M., de Hoog G. S., Verweij P. E., et al. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother: 2012; 56 5 2635 2642
154. Cortez K. J., Roilides E., Quiroz-Telles F., et al. Infections caused by Scedosporium spp. Clin Microbiol Rev: 2008; 21 1 157 197
155. Carrillo A. J., Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother: 2001; 45 7 2151 2153
156. Vfend [package insert]. New York, NY Pfizer, Inc.: 2014
157. Troke P., Aguirrebengoa K., Arteaga C., et al. Global Scedosporium Study Group. Treatment of scedosporiosis with voriconazole: Clinical experience with 107 patients. Antimicrob Agents Chemother: 2008; 52 5 1743 1750
158. Mellinghoff I. K., Winston D. J., Mukwaya G., Schiller G. J. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis: 2002; 34 12 1648 1650
159. Kesson A. M., Bellemore M. C., O'Mara T. J., Ellis D. H., Sorrell T. C. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: A case report. Clin Infect Dis: 2009; 48 9 1257 1261
160. Koehler P., Tacke D., Cornely O. A. Bone and joint infections by Mucorales, Scedosporium, Fusarium and even rarer fungi. Crit Rev Microbiol: 2014; 1 14
161. Alastruey-Izquierdo A., Cuenca-Estrella M., Monzón A., Mellado E., Rodríguez-Tudela J. L. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother: 2008; 61 4 805 809
162. Campo M., Lewis R. E., Kontoyiannis D. P. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. J Infect: 2010; 60 5 331 337
163. Nucci M., Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev: 2007; 20 4 695 704
164. Nucci M., Anaissie E. J., Queiroz-Telles F., et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer: 2003; 98 2 315 319
165. Lortholary O., Obenga G., Biswas P., et al. French Mycoses Study Group. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother: 2010; 54 10 4446 4450
166. Shobana C. S., Mythili A., Homa M., et al. In vitro susceptibility of filamentous fungi from mycotic keratitis to azole drugs. J Mycol Med: 2015; 25 1 44 49
167. Azor M., Gené J., Cano J., Guarro J. Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex. Antimicrob Agents Chemother: 2007; 51 4 1500 1503
168. Wu C. H., Lu P. L., Hsiao H. H., et al. Breakthrough Fusarium solani infection in a patient with acute myeloid leukemia receiving posaconazole prophylaxis. Ann Hematol: 2014; 93 6 1079 1081
169. Bose P., Parekh H. D., Holter J. L., Greenfield R. A. Disseminated fusariosis occurring in two patients despite posaconazole prophylaxis. J Clin Microbiol: 2011; 49 4 1674 1675
170. Kontoyiannis D. P., Bodey G. P., Hanna H., et al. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. Leuk Lymphoma: 2004; 45 1 139 141
171. Raad I. I., Hachem R. Y., Herbrecht R., et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis: 2006; 42 10 1398 1403
172. Ho D. Y., Lee J. D., Rosso F., Montoya J. G. Treating disseminated fusariosis: Amphotericin B, voriconazole or both? Mycoses: 2007; 50 3 227 231
173. Liu J. Y., Chen W. T., Ko B. S., et al. Combination antifungal therapy for disseminated fusariosis in immunocompromised patients: A case report and literature review. Med Mycol: 2011; 49 8 872 878
174. Horn D. L., Freifeld A. G., Schuster M. G., Azie N. E., Franks B., Kauffman C. A. Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance(®) registry. Mycoses: 2014; 57 11 652 658
175. Herbrecht R., Kessler R., Kravanja C., Meyer M. H., Waller J., Letscher-Bru V. Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant: 2004; 23 12 1451 1454
176. Tu E. Y., McCartney D. L., Beatty R. F., Springer K. L., Levy J., Edward D. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol: 2007; 143 2 222 227
177. Pfaller M. A., Diekema D. J., Gibbs D. L., et al. Global Antifungal Surveillance Group. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: A 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol: 2010; 48 4 1366 1377
178. Guinea J., Zaragoza Ó, Escribano P., et al. CANDIPOP Project, GEIH-GEMICOMED (SEIMC), and REIPI. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother: 2014; 58 3 1529 1537
179. Howard S. J., Cerar D., Anderson M. J., et al. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis: 2009; 15 7 1068 1076
180. Chowdhary A., Sharma C., Hagen F., Meis J. F. Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms. Future Microbiol: 2014; 9 5 697 711
181. Steinmann J., Hamprecht A., Vehreschild M. J., et al. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother: 2015; 70 5 1522 1526
182. van der Linden J. W., Camps S. M., Kampinga G. A., et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis: 2013; 57 4 513 520
183. Mann P. A., McNicholas P. M., Chau A. S., et al. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother: 2009; 53 12 5026 5034
184. Li X., Brown N., Chau A. S., et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother: 2004; 53 1 74 80
185. Snelders E., van der Lee H. A., Kuijpers J., et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med: 2008; 5 11 e219
186. Alanio A., Sitterlé E., Liance M., et al. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother: 2011; 66 2 371 374
187. Verweij P. E., Howard S. J., Melchers W. J., Denning D. W. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat: 2009; 12 6 141 147
188. Pfaller M. A., Messer S. A., Boyken L., et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol: 2008; 46 8 2568 2572
189. Denning D. W., Park S., Lass-Florl C., et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis: 2011; 52 9 1123 1129
190. Chowdhary A., Sharma C., Kathuria S., Hagen F., Meis J. F. Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India. J Antimicrob Chemother: 2014; 69 2 555 557
191. Verweij P. E., Mellado E., Melchers W. J. Multiple-triazole-resistant aspergillosis. N Engl J Med: 2007; 356 14 1481 1483
192. Mavridou E., Brüggemann R. J., Melchers W. J., Mouton J. W., Verweij P. E. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother: 2010; 54 2 860 865
193. Mellado E., Garcia-Effron G., Alcázar-Fuoli L., et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother: 2007; 51 6 1897 1904
194. Kuipers S., Brüggemann R. J., de Sévaux R. G., et al. Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole. Antimicrob Agents Chemother: 2011; 55 7 3564 3566
195. Govender N. P., Patel J., van Wyk M., Chiller T. M., Lockhart S. R.; Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa (GERMS-SA). Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008. Antimicrob Agents Chemother: 2011; 55 6 2606 2611
196. Sionov E., Chang Y. C., Garraffo H. M., Dolan M. A., Ghannoum M. A., Kwon-Chung K. J. Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole. Antimicrob Agents Chemother: 2012; 56 3 1162 1169
197. Gullo F. P., Rossi S. A., Sardi J. C., Teodoro V. L., Mendes-Giannini M. J., Fusco-Almeida A. M. Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment. Eur J Clin Microbiol Infect Dis: 2013; 32 11 1377 1391
198. Guinea J., Hagen F., Peláez T., et al. Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain. Med Mycol: 2010; 48 7 942 948
199. Krieter P., Flannery B., Musick T., Gohdes M., Martinho M., Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother: 2004; 48 9 3543 3551
200. Courtney R., Pai S., Laughlin M., Lim J., Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother: 2003; 47 9 2788 2795
201. Ezzet F., Wexler D., Courtney R., Krishna G., Lim J., Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: Comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet: 2005; 44 2 211 220
202. Farowski F., Cornely O. A., Vehreschild J. J., et al. Intracellular concentrations of posaconazole in different compartments of peripheral blood. Antimicrob Agents Chemother: 2010; 54 7 2928 2931
203. Conte J. E. Jr, DeVoe C., Little E., Golden J. A. Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. Antimicrob Agents Chemother: 2010; 54 9 3609 3613
204. Conte J. E. Jr, Golden J. A., Krishna G., McIver M., Little E., Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob Agents Chemother: 2009; 53 2 703 707
205. Blennow O., Eliasson E., Pettersson T., et al. Posaconazole concentrations in human tissues after allogeneic stem cell transplantation. Antimicrob Agents Chemother: 2014; 58 8 4941 4943
206. Courtney R., Wexler D., Radwanski E., Lim J., Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol: 2004; 57 2 218 222
207. Krishna G., Moton A., Ma L., Medlock M. M., McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother: 2009; 53 3 958 966
208. Krishna G., Ma L., Vickery D., et al. Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother: 2009; 53 11 4749 4752
209. Walravens J., Brouwers J., Spriet I., Tack J., Annaert P., Augustijns P. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations. Clin Pharmacokinet: 2011; 50 11 725 734
210. Ray J., Campbell L., Rudham S., Nguyen Q., Marriott D. Posaconazole plasma concentrations in critically ill patients. Ther Drug Monit: 2011; 33 4 387 392
211. Krishna G., AbuTarif M., Xuan F., Martinho M., Angulo D., Cornely O. A. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy: 2008; 28 10 1223 1232
212. Dolton M. J., Ray J. E., Chen S. C., Ng K., Pont L., McLachlan A. J. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother: 2012; 56 11 5503 5510
213. Shields R. K., Clancy C. J., Vadnerkar A., et al. Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother: 2011; 55 3 1308 1311
214. Lebeaux D., Lanternier F., Elie C., et al. Therapeutic drug monitoring of posaconazole: A monocentric study with 54 adults. Antimicrob Agents Chemother: 2009; 53 12 5224 5229
215. Gross B. N., Ihorst G., Jung M., Wäsch R., Engelhardt M. Posaconazole therapeutic drug monitoring in the real-life setting: A single-center experience and review of the literature. Pharmacotherapy: 2013; 33 10 1117 1125
216. Krishna G., Martinho M., Chandrasekar P., Ullmann A. J., Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy: 2007; 27 12 1627 1636
217. Kraft W. K., Chang P. S., van Iersel M. L., Waskin H., Krishna G., Kersemaekers W. M. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother: 2014; 58 7 4020 4025
218. Krishna G., Ma L., Martinho M., O'Mara E. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother: 2012; 56 8 4196 4201
219. Jung D. S., Tverdek F. P., Kontoyiannis D. P. Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. Antimicrob Agents Chemother: 2014; 58 11 6993 6995
220. Maertens J., Cornely O. A., Ullmann A. J., et al. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob Agents Chemother: 2014; 58 7 3610 3617
221. Dolton M. J., Ray J. E., Marriott D., McLachlan A. J. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother: 2012; 56 6 2806 2813
222. Howard S. J., Felton T. W., Gomez-Lopez A., Hope W. W. Posaconazole: the case for therapeutic drug monitoring. Ther Drug Monit: 2012; 34 1 72 76
223. Smith J., Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit: 2008; 30 2 167 172
224. Seyedmousavi S., Mouton J. W., Verweij P. E., Brüggemann R. J. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev Anti Infect Ther: 2013; 11 9 931 941
225. Hoenigl M., Raggam R. B., Salzer H. J., et al. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int J Antimicrob Agents: 2012; 39 6 510 513
226. Jang S. H., Colangelo P. M., Gobburu J. V. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther: 2010; 88 1 115 119
227. Heinz W. J., Zirkel J., Kuhn A., et al. Relevance of timing for determination of posaconazole plasma concentrations. Antimicrob Agents Chemother: 2011; 55 7 3621 3623
228. Sheppard D. C., Campoli P., Duarte R. F. Understanding antifungal prophylaxis with posaconazole in hematology patients: An evolving bedside to bench story. Haematologica: 2014; 99 4 603 604
229. Andes D., Marchillo K., Conklin R., et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother: 2004; 48 1 137 142
230. Campoli P., Al Abdallah Q., Robitaille R., et al. Concentration of antifungal agents within host cell membranes: A new paradigm governing the efficacy of prophylaxis. Antimicrob Agents Chemother: 2011; 55 12 5732 5739
231. Brüggemann R. J., Alffenaar J. W., Blijlevens N. M., et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis: 2009; 48 10 1441 1458
232. Wexler D., Courtney R., Richards W., Banfield C., Lim J., Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: A randomized, open-label, two-way crossover study. Eur J Pharm Sci: 2004; 21 5 645 653
233. Moton A., Krishna G., Wang Z. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers. J Clin Pharm Ther: 2009; 34 3 301 311
234. Moton A., Ma L., Krishna G., Martinho M., Seiberling M., McLeod J. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin: 2009; 25 3 701 707
235. Billaud E. M., Guillemain R., Berge M., et al. Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients. Med Mycol: 2010; 48 01 S52 S59
236. Berge M., Chevalier P., Benammar M., et al. Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis. Ther Drug Monit: 2009; 31 3 396 399
237. Bernardo V. A., Cross S. J., Crews K. R., et al. Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. Ann Pharmacother: 2013; 47 7-8 976 983
238. Jacinto P. L., Chandrasekar P. Safety of posaconazole. Expert Opin Drug Saf: 2013; 12 2 265 274
239. Raad I. I., Graybill J. R., Bustamante A. B., et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis: 2006; 42 12 1726 1734
240. Krishna G., Ma L., Martinho M., Preston R. A., O'Mara E. A new solid oral tablet formulation of posaconazole: A randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother: 2012; 67 11 2725 2730
241. Duarte R. F., López-Jiménez J., Cornely O. A., et al. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother: 2014; 58 10 5758 5765
242. Eiden C., Peyrière H., Tichit R., et al. Inherited long QT syndrome revealed by antifungals drug-drug interaction. J Clin Pharm Ther: 2007; 32 3 321 324
243. Owens R. C. Jr, Nolin T. D. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis: 2006; 43 12 1603 1611
244. Zonios D. I., Gea-Banacloche J., Childs R., Bennett J. E. Hallucinations during voriconazole therapy. Clin Infect Dis: 2008; 47 1 e7 e10
245. Aksoy F., Akdogan E., Aydin K., et al. Voriconazole-induced neuropathy. Chemotherapy: 2008; 54 3 224 227
246. Pascual A., Calandra T., Bolay S., Buclin T., Bille J., Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis: 2008; 46 2 201 211
247. Moriyama B., Henning S. A., Leung J., et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses: 2012; 55 4 290 297
248. Pakyz A., Bearman G. Adverse drug events complicate antifungal therapy for pulmonary aspergilloma. Consult Pharm: 2008; 23 10 804 808
249. Moon W. J., Scheller E. L., Suneja A., et al. Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain. Clin Infect Dis: 2014; 59 9 1237 1245
250. Thompson G. R. III, Bays D., Cohen S. H., Pappagianis D. Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy: An assessment of currently available triazoles. Antimicrob Agents Chemother: 2012; 56 1 563 564
251. Goyal R. K., Gehris R. P., Howrie D., Cogley K. M., Windreich R. M., Venkataramanan R. Phototoxic dermatoses in pediatric BMT patients receiving voriconazole. Pediatr Blood Cancer: 2014; 61 7 1325 1328
252. McCarthy K. L., Playford E. G., Looke D. F., Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis: 2007; 44 5 e55 e56
253. Miller D. D., Cowen E. W., Nguyen J. C., McCalmont T. H., Fox L. P. Melanoma associated with long-term voriconazole therapy: A new manifestation of chronic photosensitivity. Arch Dermatol: 2010; 146 3 300 304
254. Williams K., Mansh M., Chin-Hong P., Singer J., Arron S. T. Voriconazole-associated cutaneous malignancy: A literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis: 2014; 58 7 997 1002
255. Marriott D., Levy R., Doyle T., Ray J. Posaconazole-induced topiramate toxicity. Ann Intern Med: 2009; 151 2 143
256. Krishna G., Moton A., Ma L., Martinho M., Seiberling M., McLeod J. Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. J Acquir Immune Defic Syndr: 2009; 51 4 437 444
257. Brüggemann R. J., van Luin M., Colbers E. P., et al. Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers. J Antimicrob Chemother: 2010; 65 10 2188 2194
258. Heinz W. J., Grau A., Ulrich A., et al. Impact of benzodiazepines on posaconazole serum concentrations. A population-based pharmacokinetic study on drug interaction. Curr Med Res Opin: 2012; 28 4 551 557
259. Krishna G., Moton A., Ma L., et al. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: A phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther: 2009; 31 2 286 298
260. Krishna G., Ma L., Prasad P., Moton A., Martinho M., O'Mara E. Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers. Expert Opin Drug Metab Toxicol: 2012; 8 1 1 10
261. Sansone-Parsons A., Krishna G., Martinho M., Kantesaria B., Gelone S., Mant T. G. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy: 2007; 27 6 825 834
262. Krishna G., Parsons A., Kantesaria B., Mant T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin: 2007; 23 3 545 552
263. Kubiak D. W., Koo S., Hammond S. P., et al. Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants. Biol Blood Marrow Transplant: 2012; 18 9 1462 1465
264. Baciewicz A. M., Chrisman C. R., Finch C. K., Self T. H. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin: 2013; 29 1 1 12
265. Hohmann C., Kang E. M., Jancel T. Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations. Clin Infect Dis: 2010; 50 6 939 940